Evidence map›Paper›PMID 21645413›Full record

ArticleCancer cell international2011

Proteomics research on muscle-invasive bladder transitional cell carcinoma.

Hai Tao Niu, Zhen Dong, Gang Jiang, Ting Xu, Yan Qun Liu, Yan Wei Cao, Jun Zhao, Xin Sheng Wang

Abstract read
In one paragraph

Article in Cancer cell international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hai Tao Niu *Department of Urology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
Zhen Dong *Department of Urology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
Gang JiangDepartment of Radiology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
Ting XuDepartment of Geratology, The 401th Hospital of PLA, Qingdao, China.
Yan Qun LiuDepartment of Hematology, Qingdao University Medical College, Qingdao, China.
Yan Wei CaoDepartment of Urology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
Jun ZhaoDepartment of Urology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, China.
Xin Sheng WangDepartment of Urology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAimed to facilitate candidate biomarkers selection and improve network-based multi-target therapy, we perform comparative proteomics research on muscle-invasive bladder transitional cell carcinoma. Laser capture microdissection was used to harvest purified muscle-invasive bladder cancer cells and normal urothelial cells from 4 paired samples. Two-dimensional liquid chromatography tandem mass spectrometry was used to identify the proteome expression profile. The differential proteins were further analyzed using bioinformatics tools and compared with the published literature.

resultsA total of 885/890 proteins commonly appeared in 4 paired samples. 295/337 of the 488/493 proteins that specific expressed in tumor/normal cells own gene ontology (GO) cellular component annotation. Compared with the entire list of the international protein index (IPI), there are 42/45 GO terms exhibited as enriched and 9/5 exhibited as depleted, respectively. Several pathways exhibit significantly changes between cancer and normal cells, mainly including spliceosome, endocytosis, oxidative phosphorylation, etc. Finally, descriptive statistics show that the PI Distribution of candidate biomarkers have certain regularity.

conclusionsThe present study identified the proteome expression profile of muscle-invasive bladder cancer cells and normal urothelial cells, providing information for subcellular pattern research of cancer and offer candidate proteins for biomarker panel and network-based multi-target therapy.

Identifiers

PMID21645413
PMCPMC3118115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.